/

FATE

Fate Therapeutics, Inc.Closed

2.00−0.13 −6.10%USD

NasdaqGM · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.00 0.00%

Open

2.13

Prev close

2.13

Day range

1.982.13

52-week range

0.95003.23

Volume

952.47K0.57×

Mkt cap

239.64M

P/E ttm

—

Fwd P/E

-2.07

EPS ttm

-1.05

Div yield

0.00%

Earnings

Aug 13, 2026

From 52w high

−38.08%

Price Chart

Yahoo Finance · delayed

FATEOct 13, 2026O 2.13H 2.13L 1.98C 2.00−0.13 (−6.10%)Vol 953.50K

SMA 502.44
SMA 2001.89

1Y change +21.95% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

FATE Fate Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −12.66%
1 month: −13.42%
3 months: −33.11%
6 months: +49.25%
Year to date: +104.08%
1 year: +43.88%

Valuation & ownership

Market cap: 239.64M
Enterprise value: 161.55M
P/E (ttm): —
Forward P/E: -2.07
PEG ratio: —
Price / book: 1.52
Price / sales (ttm): 36.92
EV / EBITDA: -1.34
EPS (ttm): -1.05
EPS (forward): -0.9675
Beta (5y monthly): 2.53
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 119.82M
Float: 105.48M
Short % of float: 10.14%
Short ratio (days): 7.34
Held by insiders: 1.07%
Held by institutions: 69.04%
Avg volume (3m): 1.68M
50-day average: 2.45
200-day average: 1.89
52-week change: +43.88%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 31.5
vs 50-day SMA: −18.11%
vs 200-day SMA: +5.71%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.51%
Realised vol (20d, ann.): 55.1%
From 52-week high: −38.08%
From 52-week low: +110.53%

ANR

Analyst Consensus

9 analysts

Consensus

Buy

2.18 on a 1 (strong buy) – 5 (sell) scale

Mean target

5.74

+187.22% implied

Low 2.20Median 7.00High 8.00

Recommendation trend

Now5 / 6 / 0
1m ago / 6 /

DES

About Fate Therapeutics, Inc.

Yahoo Finance profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 161
Headquarters: San Diego, CA, United States
Website: fatetherapeutics.com
Officers: Dr. Bahram Valamehr M.B.A., Ph.D. President, CEO & Director
Mr. Kamal Adawi M.S., MBA CFO & Treasurer
Ms. Cindy R. Tahl J.D. Chief Legal & Compliance Officer and Corporate Secretary
Ms. Jessica Francis

SEAS

Seasonality · FATE

2013–2026 · monthly returns

Strongest month Nov +9.08%Weakest month Oct −9.16%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	21.4	24.4	-18.9	4.2	127.2	-4.9	-9.3	-2.4	-0.8	-15.6			+104.1%
2025	-21.2	-13.8	-29.5	62.0	-5.5	-7.4	-1.8	-5.5	21.2	7.1	-15.6	-14.0	−40.6%
2024	64.7	15.1	3.5	-46.2	-6.8	-10.9	62.5	-31.1	-4.6	-32.3	33.8	-47.9	−55.9%
2023	-40.9	2.7	-6.9	6.5	-16.8	-5.7	-13.2	-39.2	-15.5	-14.6	37.6	50.2	−62.9%
2022	-29.1	-16.8	12.2	-26.3	-19.1	7.3	23.2	-14.4	-14.3	-6.6	-0.5	-51.5	−82.8%
2021	-0.3	-1.0	-8.1	6.0	-12.3	13.3	-4.6	-11.5	-19.1	-9.2	2.2	6.4	−35.7%
2020	29.6	15.1	-23.9	23.3	18.4	5.8	-8.9	16.4	9.8	11.1	31.7	55.5	+364.6%
2019	18.0	3.8	11.8	-4.4	14.8	5.3	8.6	-26.0	-4.8	-3.7	4.5	25.3	+52.5%
2018	49.6	23.2	-13.3	3.5	8.4	3.6	-21.3	44.3	26.4	-23.5	23.3	-16.5	+110.0%
2017	8.8	57.1	6.1	0.9	-26.6	-3.9	-10.8	30.8	4.8	20.5	-7.8	38.9	+143.4%
2016	-36.2	-18.1	2.3	5.6	-19.5	11.1	21.8	25.6	20.0	-32.7	40.0	-14.6	−25.5%
2015	1.4	-2.4	-1.8	-0.2	28.3	3.4	9.1	-7.5	-18.4	-17.4	-4.8	-19.6	−33.0%
2014	-1.3	12.4	39.7	-29.4	1.6	-9.7	-4.4	-11.4	-4.5	-8.4	-19.7	34.1	−19.9%
2013											-6.7	12.1	+4.7%

INSD

Insider Activity · FATE

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

216.7K shares

Sells, 6 months

137.3K shares

Net shares

+79.4K

Net change in insider shares

+6.60%

Date	Insider	Transaction	Shares	Value
Aug 3, 2026	Tahl Cindy ROfficer	Sale at price 2.46 per share.	38.8K	$95.41K
Aug 3, 2026	Valamehr BahramChief Executive Officer	Sale at price 2.46 per share.	43.9K	$108.10K
May 19, 2026	Tahl Cindy ROfficer	Sale at price 1.88 per share.	25.6K	$48.08K
May 19, 2026	Valamehr BahramChief Executive Officer	Sale at price 1.88 per share.	28.9K	$54.48K
May 5, 2026	Tahl Cindy ROfficer	Conversion of Exercise of derivative security at price 1.05 - 1.32 per share.	166.7K	$208.00K
May 4, 2026	Rastetter William HDirector	Conversion of Exercise of derivative security at price 1.69 per share.	25K	$42.25K
May 4, 2026	Epstein Robert SDirector	Conversion of Exercise of derivative security at price 1.69 per share.	25K	$42.25K
Jan 14, 2026	Tahl Cindy ROfficer	Stock Award(Grant) at price 0.00 per share.	100K	—
Jan 14, 2026	Valamehr BahramChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	335K	—
Jan 14, 2026	Adawi KamalChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	25K	—
Jan 8, 2026	Tahl Cindy ROfficer	Sale at price 1.06 per share.	10.6K	$11.28K
Jan 8, 2026	Valamehr BahramChief Executive Officer	Sale at price 1.07 per share.	5.2K	$5.56K
Oct 19, 2025	Adawi KamalChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	75K	—
Aug 3, 2025	Tahl Cindy ROfficer	Sale at price 1.06 per share.	9K	$9.57K
Aug 3, 2025	Valamehr BahramChief Executive Officer	Sale at price 1.06 per share.	14.5K	$15.40K
Jan 14, 2025	Tahl Cindy ROfficer	Stock Award(Grant) at price 0.00 per share.	70K	—
Jan 14, 2025	Bressi Jerome CharlesOfficer	Stock Award(Grant) at price 0.00 per share.	65K	—
Jan 9, 2025	Tahl Cindy ROfficer	Sale at price 1.55 per share.	5.7K	$8.76K
Jan 9, 2025	Valamehr BahramChief Executive Officer	Sale at price 1.54 per share.	8.7K	$13.41K
Jan 9, 2025	Bressi Jerome CharlesOfficer	Sale at price 1.55 per share.	6K	$9.27K

13F

Investors Holding FATE

latest 13F filings of 29 followed managers

Investors holding FATE
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$8.1M	0.01%	2.98M	—	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

FATE

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

FATE

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Fate Therapeutics, Inc.

Seasonality · FATE

Insider Activity · FATE

Congress Trades · FATE

Investors Holding FATE

Investors Holding FATE

Congress Trades · FATE

Insider Activity · FATE

Seasonality · FATE

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Fate Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News